

When to refer to a Dermatologist

Badri Modi, M.D.
City of Hope
Division of Dermatology





Disclosures

- No relevant financial relationships to disclose
- I *will not* be discussing non-FDA approved indications during my presentation.



Cutaneous adverse events

- All grade: 35-50%
- Grade 3 or more: 2%
- 20% experience skin AE-related interruption of therapy
- More reaction with anti-CTLA-4 than with anti-PD1/PDL1
- Onset of rash typically occurs around 3 weeks post-exposure



National Cancer Institute Grading of Skin AEs

| Grade | Skin lesion | BSA % | Symptomatic |
|-------|------------------------------|-------|-----------------------|
| 1 | Macules, papules | < 50% | No |
| 2 | Macules, papules | < 50% | Yes (pruritus, other) |
| 3 | Macules, papules, blisters | > 50% | Yes (pruritus, other) |
| 4 | Exfoliation, ulcer, blisters | | Yes (pruritus, other) |
| 5 | Death | | |

Minkis, et al. "The risk of rash associated with..." JAAD. 2013.

© 2017 Society for Immunotherapy of Cancer




Macules & papules

- “Morbilliform”
- Typically responds to topical steroids
- Considered grade 3 if BSA > 50%
- If not improved with topical steroids, would refer to Derm



Bullous Pemphigoid

- Autoimmune blistering disorder
- Antibodies against basement membrane
- Treatment: **Topical** vs. oral steroid



Rofe, et al. "Severe bullous pemphigoid..." Clin and Exp Derm. 2016.
Joy, et al. "A comparison of oral and topical steroids..." NEJM. 2002.



Before & after treatment



Stevens-Johnson Syndrome




Saw, et al. "Pembrolizumab-induced SJS..." Eur J Cancer. 2017.

© 2017 Society for Immunotherapy of Cancer




Pembrolizumab-induced vasculopathy



Brown, et al. "Pembrolizumab induced ischemic vasculopathy." *in press.*

© 2017 Society for Immunotherapy of Cancer





Sweet syndrome

Kyllo, et al. "Ipilimumab-associated Sweet syndrome...." JAAD. 2013.

© 2017 Society for Immunotherapy of Cancer

When to refer

- Clinical symptoms that should trigger a referral
 - Blisters
 - Skin pain
 - Mucosal surface involvement
 - Fever or clinically toxic
- Other reasons to refer
 - Skin biopsy needed
 - Unclear diagnosis
 - Not responding to initial treatment
 - If you are considering prescribing oral steroids



ADVANCES IN
Cancer
IMMUNOTHERAPY™

A circular graphic logo consisting of several concentric, overlapping rings in shades of green and blue, creating a sense of depth and movement.

Thank you

Badri Modi, M.D.

bamodi@coh.org



Society for Immunotherapy of Cancer